Ultrafiltration Versus IV Diuretics in Worsening Heart Failure
A trial with no phase registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 167 participants.
Also called NCT05318105
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 167 participants
- Sponsor
- Nuwellis, Inc.
- Registry
-
NCT05318105
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Terminated
Technical summary
Registry record NCT05318105. Randomized; no masking; primary purpose treatment. Start 2022-06-28 (actual); primary completion 2025-10-06 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Ultrafiltration Versus IV Diuretics in Worsening Heart Failure
- Acronym
- REVERSE-HF
- Condition
- Heart Failure (for Example, Fluid Overload)
- Condition
- Heart Failure
- Condition
- Fluid Overload
- Intervention (Device)
- Aquadex Smartflow® System
- Intervention (Drug)
- IV Loop Diuretics
- Lead sponsor
- Nuwellis, Inc.
Record details
- Record id
cardio:ct-nct05318105- Content hash
1f21c9da361ec435c988de015e356a69ef9586b6a556abcd84c09700739bc322